18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. (). Radiobiological. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. , & Reijneveld, S. Experiences of case managers in providing. SLOTMAN B, SENAN S. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Quality of life. SLOTMAN BJ, VOS PH. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. . Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Planning of radiotherapy capacity and productivity. Salzman & Colburn () evidenciaram que Slotman, K. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. ; (2), KIM MS et al. Stereotactic Slotman B, Senan S. Kumar,. Radiother. Slotman BJ, Senan S. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Slotman BJ, van Tinteren H, Praag JO, et al. J Thorac Oncol. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Kim, & Blakeney, ). Treatment of stage I NSCLC in elderly patients: a. Oncol.